Recruiting Clinical Trials

Displaying 1 - 10 of 34 result(s)
Study Title Condition Phase Location
A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive Phase 3
  • Country: 
    Czech Republic
  • Country: 
    France
  • Country: 
    Hungary
  • Country: 
A 12-week, Multicenter, Randomized, Double-blind, Parallel-arm, Placebo-controlled Study to Assess the Efficacy and Safety of CSJ117, When Added to Existing Asthma Therapy in Patients ≥ 18 Years of Age With Severe Uncontrolled Asthma. Asthma Phase 2
  • Country: 
    United States
  • Country: 
    Argentina
  • Country: 
    Belgium
  • Country: 
A 24-week, Multicenter, Randomized, Double-blind, Parallel-arm, Placebo-controlled Extension Study to Assess the Safety of CSJ117, When Added to Existing Standard of Care Asthma Therapy in Patients ≥18 Years of Age Asthma Phase 2
  • Country: 
    United States
  • Country: 
    Czech Republic
  • Country: 
    Hungary
  • Country: 
A Randomized, Subject and Investigator Blinded, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of CMK389 in Patients With Moderate to Severe Atopic Dermatitis Atopic Dermatitis Phase 2
  • Country: 
    Czech Republic
  • Country: 
    Germany
  • Country: 
    Hungary
  • Country: 
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer Prostatic Neoplasms Phase 3
  • Country: 
    United States
  • Country: 
    Austria
  • Country: 
    Czech Republic
  • Country: 
A Phase II, Open Label, Randomized, Parallel Arm Study of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy Gemcitabine/Nab-paclitaxel, and Gemcitabine/Nab-paclitaxel Alone in First-line Metastatic Pancreatic Ductal Adenoca ... Metastatic Pancreatic Ductal Adenocarcinoma Phase 2
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    Austria
  • Country: 
A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomo ... Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic Phase 3
  • Country: 
    United States
  • Country: 
    Argentina
  • Country: 
    Australia
  • Country: 
A Subject and Investigator Blinded, Randomized, Placebo-controlled, Repeat-dose, Multicenter Study to Investigate Efficacy, Safety, and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis Pulmonary Sarcoidosis Phase 2
  • Country: 
    United States
  • Country: 
    Czech Republic
  • Country: 
    Denmark
  • Country: 
A Randomized, Subject and Investigator Blinded, Placebo-controlled and Multi-center Platform Study, to Assess Efficacy and Safety of Different Investigational Drugs in Patients With Moderate to Severe Hidradenitis Suppurativa Hidradenitis Suppurativa Phase 2
  • Country: 
    United States
  • Country: 
    Austria
  • Country: 
    Belgium
  • Country: 
A Three-period Multicenter Study, With a Randomized-withdrawal, Double-blinded, Placebo-controlled Design in Period 2 to Evaluate the Clinical Efficacy, Safety, and Tolerability of MAS825 in NLRC4-GOF Patients NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis) Phase 2
  • Country: 
    United States
  • Country: 
    Czech Republic
  • Country: 
    France
  • Country: